新生血管性年龄相关性黄斑变性抗血管内皮生长因子治疗一年后视力结局的预测因素
该研究基于法国GEFAL研究,纳入年龄≥50岁、存在黄斑中心凹下新生血管性年龄相关性黄斑变性的患者,随机接受雷珠单抗或贝伐珠单抗治疗(先每月3次玻璃体内注射,之后按需治疗),分析治疗1年后最佳矫正视力(BCVA)结局的预测因素。多因素分析显示,视网膜内积液、中心子区黄斑厚度≤277 μm、以经典型为主脉络膜新生血管及脉络膜新生血管总面积与1年时BCVA较低及改善较少相关。
要点
- 视网膜内积液与新生血管性年龄相关性黄斑变性抗血管内皮生长因子治疗后视力预后不良相关。
- 基线中心子区黄斑厚度≤277 μm、以经典型为主脉络膜新生血管及脉络膜新生血管总面积较大与1年BCVA较低及改善较少相关。
- 符合再治疗标准但未接受相应注射的患者结局显著更差(仅单因素分析检验)。
核心结论
- 该研究确认了治疗后1年BCVA评分的预测因素;视网膜内积液的存在与不良预后相关。
研究设计与样本
- GEFAL研究为随机对照研究,纳入年龄≥50岁、存在黄斑中心凹下新生血管性年龄相关性黄斑变性的患者,随机接受雷珠单抗或贝伐珠单抗治疗(先每月3次玻璃体内注射,之后按需治疗)。
主要发现
- 多因素分析显示,视网膜内积液、中心子区黄斑厚度≤277 μm、以经典型为主脉络膜新生血管及脉络膜新生血管总面积与1年时BCVA较低及改善较少相关(均P≤0.01)。
- 色素上皮脱离与基线BCVA较高分别与BCVA改善较少相关(P=0.03、P=0.05)。
- 符合再治疗标准但未接受相应注射的患者结局显著更差(仅单因素分析检验)。
关键数值与推荐
- 多因素分析中,视网膜内积液、中心子区黄斑厚度≤277 μm、以经典型为主脉络膜新生血管及脉络膜新生血管总面积与1年BCVA较低及改善较少相关,均P≤0.01。
- 色素上皮脱离与BCVA改善较少相关,P=0.03;基线BCVA较高与BCVA改善较少相关,P=0.05。
临床怎么用
- 原文未据此给出推荐。
局限性
- 符合再治疗标准但未接受相应注射与不良结局的关联仅在单因素分析中检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine predictors of best-corrected visual acuity (BCVA) outcomes 1 year after ranibizumab or bevacizumab treatment for neovascular age-related macular degeneration, within the French Study Group Avastin versus Lucentis for neovascular age-related macular degeneration (GEFAL). METHODS: Patients aged ≥50 years presenting subfoveal neovascular age-related macular degeneration were randomized to receive ranibizumab or bevacizumab (3 monthly intravitreal injections followed by an as-needed regimen). The main outcome measures were BCVA and its change from baseline at 1 year. Variables with a P value <0.20 in the univariate model and/or which were clinically relevant were included in the multivariate analysis. RESULTS: The following baseline factors were associated with a lower BCVA score at 1 year and with less improvement in BCVA (multivariate analysis): intraretinal fluid, thickness of central subfield macular ≤277 μm, predominantly classic choroidal neovascularization, and total area of choroidal neovascularization (all P ≤ 0.01). Pigment epithelium detachment and high baseline BCVA were associated with less improvement in BCVA (P = 0.03, P = 0.05, respectively). Patients who met retreatment criteria but did not receive the corresponding injection had significantly poorer outcomes (only tested in the univariate analysis). CONCLUSION: This study confirms the predictors of BCVA score at 1 year posttreatment; the presence of intraretinal fluid was associated with a poor prognosis.
引用
- Kodjikian L, Decullier E, Souied EH, et al. PREDICTORS OF ONE-YEAR VISUAL OUTCOMES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2018. PMID: 28654629. doi:10.1097/IAE.0000000000001736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。